Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer
April 19, 2026
April 19, 2026
PHILADELPHIA, Pennsylvania, April 19 [Category: Medical] -- The American Association for Cancer Research posted the following news release:
* * *
Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer
*
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors
SAN DIEGO - . . .
* * *
Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer
*
Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors
SAN DIEGO - . . .